- In 2023, QIAGEN received CE certification for its In Vitro Diagnostic (IVD) kit and NeuMoDx automated testing platform. This certification significantly enhanced the company’s market position and revenue, reflecting a key milestone in the adoption of their advanced diagnostic technologies. The approval paves the way for the broader integration of QIAGEN's innovative solutions across healthcare settings, facilitating quicker and more accurate diagnostic results, which are crucial for improving patient outcomes and expanding access to decentralized care
- In 2023, Danaher Corporation launched the Dxl 9000 Access Immunoassay Analyzer, which is capable of performing up to 215 tests per hour. This strategic move strengthened Danaher’s portfolio within the point-of-care diagnostics sector, focusing on enhancing testing efficiency. The introduction of this high-throughput analyzer addresses the growing demand for rapid, high-volume diagnostic testing, particularly in clinical environments where efficiency and accuracy are critical for improving patient care and operational workflows
- In 2022, Genes2Me Pvt. Ltd introduced the Rapi-Q Point of Care RT-PCR solution, designed for the detection of human papillomavirus (HPV) and tuberculosis. The device, which holds CE-IVD certification, delivers rapid results in under 45 minutes, offering superior performance, high sensitivity, and ease of use. This innovation meets the increasing demand for fast, reliable diagnostic solutions that enhance patient management and treatment outcomes, particularly in the detection of infectious diseases such as HPV and tuberculosis
- In 2022, LumiraDx Healthcare introduced its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test in India. This innovative diagnostic solution is designed to meet the needs of clinical settings by helping reduce unnecessary antibiotic prescriptions, a crucial step in combating antimicrobial resistance (AMR). This development aligns with the increasing focus on improving diagnostic accuracy and promoting responsible antibiotic use. The introduction of such advanced diagnostic tools supports efforts to address AMR while enhancing patient care and optimizing healthcare resources in the region
- In 2022, Genes2Me Pvt. Ltd. introduced the Rapi-Q Point of Care RT-PCR solution for the detection of human papillomavirus (HPV) and tuberculosis. This device, which carries CE-IVD certification, is distinguished by its user-friendly design, providing rapid results in less than 45 minutes, alongside exceptional sensitivity and reliable detection capabilities. The launch of this solution addresses the growing need for efficient, accurate, and timely diagnostic tools, particularly in the detection of infectious diseases like HPV and tuberculosis, thereby supporting improved patient outcomes and streamlining healthcare processes
